Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
EVAMIST vs NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Evamist (estradiol transdermal spray) is a form of estrogen hormone replacement therapy. Estrogens diffuse into target cells and bind to estrogen receptors, which then translocate to the nucleus and regulate gene transcription, leading to estrogenic effects.
Pentazocine is a mixed agonist-antagonist opioid that binds to mu-opioid receptors (partial agonist) and kappa-opioid receptors (agonist), producing analgesia. Naloxone is a pure opioid antagonist that competitively blocks mu, kappa, and delta receptors; when administered orally, naloxone undergoes extensive first-pass metabolism, reducing systemic absorption and primarily blocking the effects of pentazocine if the combination is misused parenterally.
Treatment of moderate to severe vasomotor symptoms due to menopause,Off-label: Prevention of postmenopausal osteoporosis (not FDA-approved for this indication)
Moderate to severe pain relief; combinations are used to reduce abuse potential.
1.53 mg per actuation (as estradiol hemihydrate); 1 spray to the inner forearm once daily.
Oral: One tablet (naloxone 0.5 mg / pentazocine 50 mg) every 3-4 hours as needed for pain; maximum 12 tablets daily.
Terminal elimination half-life is 4 hours; clinical context: dosing every 6-8 hours maintains therapeutic levels
Pentazocine has an elimination half-life of 2-3 hours in healthy adults, which may be prolonged in patients with hepatic impairment. Naloxone has a terminal half-life of 0.5-1.5 hours in adults, with a rapid decline in plasma levels; the short half-life limits its duration of opioid antagonism.
Estradiol is primarily metabolized in the liver via CYP3A4 and other cytochrome P450 enzymes. It is also metabolized in the gastrointestinal tract and skin. Major metabolites include estrone and estriol, which are conjugated (sulfates and glucuronides) and excreted in urine.
Pentazocine is metabolized primarily by hepatic conjugation (glucuronidation) and oxidation via CYP2C19 and CYP2D6; naloxone is extensively metabolized by the liver, primarily via glucuronidation (UGT2B7).
Renal (90%) as metabolites; fecal (<5%); biliary (<1%)
Pentazocine is primarily metabolized in the liver and excreted in urine as conjugates of glucuronide and sulfate, with about 60% of a dose excreted renally within 24 hours as metabolites and unchanged drug (less than 5% unchanged). Naloxone undergoes extensive hepatic metabolism to naloxone-3-glucuronide, which is excreted renally; approximately 50% of a dose is excreted as conjugates in urine within 6 hours.
80% bound to albumin and alpha-1-acid glycoprotein
Pentazocine: Approximately 35-65% bound to plasma proteins (mainly albumin). Naloxone: Approximately 32-45% bound to plasma proteins (mainly albumin).
3-5 L/kg; indicates extensive tissue distribution
Pentazocine: Vd ~2-3 L/kg, indicating extensive tissue distribution. Naloxone: Vd ~2-3 L/kg, also indicating wide distribution.
Intranasal: 70%; oral: not applicable (first-pass metabolism)
Oral pentazocine: 20-30% due to first-pass metabolism. Intramuscular pentazocine: 100%. Subcutaneous pentazocine: 100%. Oral naloxone: <2% due to extensive first-pass metabolism. Intramuscular and subcutaneous naloxone: 100%. Intravenous: 100% for both.
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (Cr Cl <30 m L/min); use with caution.
GFR 30-50 m L/min: Administer every 6 hours; GFR 10-29 m L/min: Administer every 8-12 hours; GFR <10 m L/min: Administer every 12 hours or consider alternative.
Contraindicated in Child-Pugh Class B and C (moderate to severe hepatic impairment). No data for mild impairment; use with caution.
Child-Pugh Class A: No adjustment; Child-Pugh Class B: Reduce dose by 50% or extend interval; Child-Pugh Class C: Avoid use.
Not indicated for use in pediatric patients. Safety and efficacy not established.
Not recommended for children under 12 years. For older children (≥12 years): Pentazocine 50 mg (with naloxone 0.5 mg) orally every 3-4 hours as needed; maximum 6 tablets daily.
No specific dose adjustment recommended; however, initiate at lowest effective dose due to increased risk of adverse effects (e.g., thromboembolism, malignancy) in elderly.
Initiate with half the usual adult dose (one-half tablet) and titrate carefully due to increased sensitivity and risk of respiratory depression.
Estrogen therapy increases the risk of endometrial cancer in women with an intact uterus. Use of unopposed estrogens is associated with an increased risk of endometrial hyperplasia and carcinoma. Additionally, estrogens should not be used to prevent cardiovascular disease or dementia. The Women's Health Initiative (WHI) study reported increased risks of stroke, deep vein thrombosis, pulmonary embolism, and breast cancer with estrogen-alone therapy.
Risk of respiratory depression, particularly in elderly, cachectic, or debilitated patients; risk of addiction, abuse, and misuse; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy; risk of life-threatening respiratory depression when used with benzodiazepines or other CNS depressants.
Risk of endometrial cancer: Use progestin in women with intact uterus.,Cardiovascular disorders: Increased risk of stroke, DVT, pulmonary embolism, especially in smokers and older women.,Breast cancer: Increased risk with long-term use.,Dementia: Increased risk in women ≥65 years old.,Gallbladder disease.,Hypercalcemia in patients with breast cancer and bone metastases.,Retinal vascular thrombosis: Discontinue if sudden vision loss occurs.,Fluid retention: Use with caution in patients with conditions exacerbated by edema.,Hypothyroidism: May need increased thyroid replacement dose.,Hepatic impairment: Contraindicated in severe liver disease.
Respiratory depression; hypotension; increased intracranial pressure; seizure risk (pentazocine); opioid-induced hyperalgesia; adrenal insufficiency; severe hypotension; interaction with MAOIs; risk of dependence and withdrawal; gastrointestinal obstruction; impaired renal or hepatic function; head injury.
Undiagnosed abnormal genital bleeding,Known, suspected, or history of breast cancer,Known or suspected estrogen-sensitive neoplasia,Active or history of deep vein thrombosis or pulmonary embolism,Active or history of arterial thromboembolic disease (e.g., stroke, MI),Known thrombophilic disorders (e.g., Protein C, S, or antithrombin deficiency),Hepatic impairment or disease,Pregnancy,Hypersensitivity to estradiol or any ingredient
Hypersensitivity to pentazocine or naloxone; significant respiratory depression; acute or severe bronchial asthma; GI obstruction; known or suspected paralytic ileus; patients receiving MAOIs or within 14 days.
Grapefruit and grapefruit juice may increase estradiol levels; avoid excessive consumption. No other significant food interactions reported.
No specific food interactions are reported for this combination. However, grapefruit juice may theoretically affect metabolism via CYP3A4 (pentazocine is metabolized by CYP3A4), but clinical significance is unknown. Advise patients to maintain a consistent diet.
Evamist (estradiol transdermal spray) is contraindicated in pregnancy. First trimester exposure is associated with congenital anomalies including cardiovascular and limb defects. Second and third trimester exposure increases risk of urogenital abnormalities and potential long-term reproductive tract effects in offspring. Use is not recommended at any gestational stage.
Pentazocine crosses the placenta; naloxone has limited placental transfer. No well-controlled human studies. First trimester: Risk cannot be excluded; avoid if possible. Second/Third trimester: Chronic use may cause fetal dependence; neonatal withdrawal syndrome reported. High doses near term may cause neonatal respiratory depression.
Estradiol is excreted in breast milk. The milk-to-plasma ratio is approximately 0.1-0.2. Studies show low concentrations in milk, but long-term effects on the infant are unknown. Evamist is not recommended during breastfeeding due to potential hormonal disruption and reduced milk production.
Pentazocine is excreted in breast milk in small amounts (estimated relative infant dose <3%). Naloxone is poorly bioavailable orally. Generally considered compatible with breastfeeding; monitor infant for sedation or poor feeding. M/P ratio for pentazocine is approximately 1.0.
No dosing adjustments applicable as Evamist is contraindicated in pregnancy. In the non-pregnant state, no dosage adjustment is needed. Pharmacokinetic changes during pregnancy (increased clearance, volume of distribution) are not relevant as the drug should not be used.
No established dose adjustments for pregnancy; however, pharmacokinetic changes (increased volume of distribution, enhanced clearance) may require higher or more frequent doses of pentazocine for adequate analgesia. Use lowest effective dose and shortest duration.
Apply EVAMIST to clean, dry, intact skin of the axilla or inner thigh. Avoid application to irritated or broken skin. Rotate application sites to minimize local skin reactions. Do not apply to the breast or vaginal area. For optimal absorption, wait at least 1 hour after application before showering or swimming. Monitor serum estradiol levels if inadequate symptom relief or adverse effects occur.
Naloxone in this fixed-dose combination is included to deter opioid abuse by reversing euphoria. The pentazocine component is a mixed agonist-antagonist opioid; naloxone has poor oral bioavailability but becomes active parenterally, precipitating withdrawal in opioid-dependent individuals. Use with caution in patients with impaired renal or hepatic function. Monitor for respiratory depression, especially in opioid-naive patients, as pentazocine alone can cause respiratory depression.
Apply the gel to clean, dry skin on your armpit or inner thigh.,Rotate application sites daily to avoid skin irritation.,Avoid applying to the breast or vaginal area.,Do not wash the application area for at least 1 hour after applying.,Keep away from children and pets; wash hands thoroughly after application.,Do not use if you are pregnant, breastfeeding, or have a history of certain cancers.,Report any unusual vaginal bleeding, breast lumps, or signs of blood clots immediately.
Take exactly as prescribed; do not crush or inject tablets, as injected naloxone can cause severe withdrawal in opioid-dependent individuals.,This medication contains naloxone to discourage misuse; injection will cause withdrawal symptoms.,Report any signs of withdrawal (e.g., nausea, vomiting, sweating, agitation) or breathing difficulty.,Avoid alcohol and other central nervous system depressants as they increase risk of respiratory depression.,Do not use with other opioids unless directed, as effects are unpredictable.,Keep out of reach of children; accidental ingestion may cause severe respiratory depression.
No interactions on record
"Cobicistat is a potent CYP3A4 inhibitor used to boost the pharmacokinetics of antiretroviral agents like atazanavir and darunavir. Naloxone primarily undergoes glucuronidation via UGT1A6 and UGT2B7, with minor CYP3A4 metabolism. Concomitant use with Cobicistat may modestly increase naloxone exposure due to CYP3A4 inhibition, but this is unlikely to be clinically significant given naloxone's wide therapeutic index and short half-life."
"Fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), is primarily metabolized by cytochrome P450 (CYP) 1A2 and 2D6. Naloxone, an opioid antagonist, is reported to inhibit CYP1A2, potentially decreasing the clearance of fluvoxamine. This interaction may lead to increased fluvoxamine plasma concentrations, elevating the risk of serotonin syndrome, QT prolongation, and other dose-dependent adverse effects, especially in patients receiving high doses or those with hepatic impairment."
"Naloxone, an opioid receptor antagonist, may inhibit the cytochrome P450 isoenzyme CYP3A4, which is responsible for the metabolism of ivacaftor. Concomitant administration can lead to reduced clearance of ivacaftor, resulting in elevated serum concentrations. This increase may potentiate the therapeutic effects and adverse reactions of ivacaftor, such as hepatotoxicity and QT prolongation."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about EVAMIST vs NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE, answered by our medical review team.
EVAMIST is a Estrogen Replacement that works by Evamist (estradiol transdermal spray) is a form of estrogen hormone replacement therapy. Estrogens diffuse into target cells and bind to estrogen receptors, which then translocate to the nucleus and regulate gene transcription, leading to estrogenic effects.. NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE is a Opioid Agonist-Antagonist that works by Pentazocine is a mixed agonist-antagonist opioid that binds to mu-opioid receptors (partial agonist) and kappa-opioid receptors (agonist), producing analgesia. Naloxone is a pure opioid antagonist that competitively blocks mu, kappa, and delta receptors; when administered orally, naloxone undergoes extensive first-pass metabolism, reducing systemic absorption and primarily blocking the effects of pentazocine if the combination is misused parenterally.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between EVAMIST and NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of EVAMIST is: 1.53 mg per actuation (as estradiol hemihydrate); 1 spray to the inner forearm once daily.. The standard adult dose of NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE is: Oral: One tablet (naloxone 0.5 mg / pentazocine 50 mg) every 3-4 hours as needed for pain; maximum 12 tablets daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between EVAMIST and NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. EVAMIST is classified as Category C. Evamist (estradiol transdermal spray) is contraindicated in pregnancy. First trimester exposure is associated with congenital anomalies including cardiovascular and limb defects. S. NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE is classified as Category A/B. Pentazocine crosses the placenta; naloxone has limited placental transfer. No well-controlled human studies. First trimester: Risk cannot be excluded; avoid if possible. Second/Thi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.